Travere Therapeutics (TVTX) Non-Current Debt (2014 - 2015)

Travere Therapeutics' (TVTX) quarterly Non-Current Debt came in at $40.8 million in Q1 2015, up 1.6% on a QoQ basis from $40.2 million in Q3 2014.

Travere Therapeutics (TVTX) Non-Current Debt (2014 - 2015) Analysis & Trends

Travere Therapeutics (TVTX) has 2 years of Non-Current Debt data on file, last reported at $40.8 million in Q1 2015.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 1.99 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 882.16 Mn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - 8.96 Bn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 546.77 Mn
10 Travere Therapeutics 5.85 Bn 5.85 Bn 162.52 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2015 40.80 Mn
Sep 30, 2014 40.16 Mn